Biotech services buoy Merck KGaA as countries reopen

6 August 2020
merck_kgaa_new_large

A more upbeat financial results statement from Germany’s Merck KGaA (MRK: DE) reflects rebounding sales in key markets, with falling COVID-19 rates enabling countries to relax lockdown measures.

In line with analysts’ expectations, sales rose by 3.7% to 4.1 billion euros ($4.86 billion) in the second quarter, while earnings before interest, taxes, depreciation, and amortization (EBITDA) fell 5.7% to 1.1 billion euros.

Merck said its healthcare and performance materials units have been more severely affected by the COVID-19 pandemic, compared with life sciences.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology